5492
Mohamed Ahmed Shawky Moustafa Hussein
Bmi1 Role In Hepatic Progenitor Cell Expansion And Hepatocellular Carcinoma Development
Hepatocellular, carcinoma, BMI1, A1compound
Hepatocellular carcinoma (HCC) is unique among cancers occurring mostly in patients with chronic inflammation and cirrhosis. HCC is the fifth most common form of cancer worldwide and the third most common cause of cancer-related deaths. Surgery is best therapeutic treatment, but most symptomatic HCC cases are in advanced stage where surgical resection is not possible. We set out to test whether targeting BMI1 will interfere with HCC cell survival. A novel compound with antitumor activity against HCC has been developed at Rutgers University, and was utilized in this study. The A1 compound showed knockdown of BMI1 expression in liver cancer cell lines. The compound also impacted downstream BMI1 targets. This compound reduced tumor initiation in liver cells in vitro and demonstrated antitumor activity in zebrafish xenografts. The A1 compound downregulated BMI1 expression with cell growth arrest, largely without induction of apoptosis. Further validation of the antitumor activity of this compound holds promise for the development of new therapeutic modality to target self-renewal of HCC stem-like cells.
2015
M.Sc
Cairo
Medicine